A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type. | C4C

The Avanir 305 study is investigating a new therapy for people with a diagnosis of probable Alzheimer’s Disease with agitation. The study design means that participants will be allocated to either one of the two active treatment groups or the placebo (dummy drug) group, so there is a 40% chance that a participant may be receiving the dummy drug. To prevent biasness, the study will be double-blinded, which means neither the participant nor the research team will know whether the participant has been allocated to the treatment or the placebo group. We would like to perform a CRIS search to identify MHOA (Mental Health of Older Adults & Dementia) patients who may be eligible for this study. This is a multi centre study, where King’s College London is one of the participating site’s, collaborating with three participating diagnostic specialist memory clinics, Community Mental Health Teams and Care Home Intervention Teams in South London & Maudsley NHS foundation Trust and we (MHOA (Mental Health of Older Adults & Dementia) research assistants) will be contacting potentially eligible patients ourselves.